The US Food and Drug Administration (FDA) has approved Takeda’s oral orexin receptor agonist, oveporexton, for a form of narcolepsy – opening up the market for a drug class that key opinion leaders (KOLs) are touting as a new frontier in the indication.
The twice-daily therapy, which will be marketed as Orzeyful, will soon become available to American patients with narcolepsy type 1; a lifelong sleep disorder characterised by daytime sleepiness, sudden muscle weakness and other debilitating symptoms like nighttime sleep disruptions, hallucinations and sleep paralysis.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The FDA approved Orzeyful based on the results of the Phase III FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials, in which the therapy significantly improved patients’ ability to remain awake during the day over those in the placebo arm. The drug also offered meaningful improvements across a wide spectrum of narcolepsy symptoms, including disrupted nighttime sleep, hallucinations and sleep paralysis.
Orzeyful’s US approval extends its market reach, following the drug’s Chinese approval back in July 2026.
Unlike current treatments, which only manage certain symptoms of the disease, Orzeyful targets the root cause of narcolepsy type 1 by binding to the orexin receptor 2 (OX2R), which is involved in regulating wakefulness and sleep-wake cycles. By triggering the activity of this receptor, the orexin receptor drug class can account for the loss of orexin-producing nerve cells that are lost in patients with type 1 narcolepsy.
Now that Orzeyful is FDA-approved in narcolepsy type 1, Takeda is looking to secure a controlled substance classification for the drug from the Drug Enforcement Agency (DEA), which the Japanese pharma giant expects within 90 days. Once the drug obtains this classification, Takeda will make Orzeyful available through speciality pharmacies.
Narcolepsy market heats up
Orzeyful’s approval marks a first for patients with type 1 narcolepsy, as it becomes the only disease-modifying therapy to get the regulatory green light – a milestone which Giuseppe Plazzi, head of Sleep Laboratories and the Outpatient Clinic for Narcolepsy and CNS Hypersomnias at IRCCS Institute of Neurological Sciences, previously told Pharmaceutical Technology could offer patients “huge improvements” in quality of life.
Before Orzeyful’s FDA go-ahead, GlobalData analysts earmarked the drug’s approval as one of the most significant events of Q3 2026 due to its ability to “transform the treatment landscape for type 1 narcolepsy.
While Takeda will hold the first-to-market advantage, this headstart may not last long, as several OX2R agonists are now making their way through the late-stage clinical pipeline. This includes Alkermes’ alixorexton, which recently posted positive nine-month data through a long-term extension study.
Previously, senior GlobalData healthcare researcher, Irena Maragkou, noted that Takeda will likely face fierce competition from Alkermes, as alixorexton may offer a better dosing schedule and a potentially wider treatment scope.
“Emerging competition from other orexin receptor agonists and variability in patient response may influence its long-term market positioning,” commented Maragkou.
Another player vying for a slice of the narcolepsy market is Eli Lilly, which recently bought sleep disorder biotech, Centessa Pharmaceuticals, for $7.8bn to claim its lead candidate and narcolepsy hopeful, cleminorexton. The drug has already secured Phase II victories across a range of sleep-wave cycle disorders.
